test

Sarah B Goldberg MD, MPH

Assistant Professor of Medicine (Medical Oncology)

Clinical Interests

Lung Cancer; Thoracic Oncology; Personalized Medicine


Board Certifications

2009
Internal Medicine, Board Certified
Hematology, Internal Medicine, Board Eligible
2012
Medical Oncology, Board Certified

Clinical Trials

ConditionsStudy Title
Non Small Cell Lung Cancer, Lung Cancer, and LungA Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (CIRB) (SWOG S0819)
Lung Cancer, Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Ill-Defined Sites, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, and ThyroidA Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Non Small Cell Lung Cancer and LungA Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
LungA Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

More Clinical Trials...

Edit Profile